Core Viewpoint - San Sheng Co., Ltd. expects a revenue of 910 to 1,070 million yuan for 2025, down from 1,196 million yuan in the same period last year, indicating a decline due to financial constraints and changes in market conditions affecting the construction materials and pharmaceutical sectors [1] Financial Performance - The company anticipates a net loss of 530 to 380 million yuan for 2025, compared to a net loss of 650 million yuan in the previous year, representing a year-on-year decrease of 18.48% to 41.55% [1] - The decline in performance is attributed to tight funding and adverse market conditions leading to decreased performance in both the construction materials and pharmaceutical segments, along with provisions for expected liabilities and asset impairment [1] Stock Market Implications - The company's stock has been subjected to delisting risk warnings, and additional risk warnings have been applied. If the 2025 annual report reveals certain conditions, the stock may face the risk of termination of listing [1]

今年以来港股上市公司回购金额前十情况 2026年以来，港股上市公司继续积极开展回购，大额回购频繁出现。 Wind数据显示，截至1月26日，2026年以来合计有112家港股上市公司进行了回购，累计回购股票数量为4.13亿股，回购金额为120.77亿港 元。2025年同期合计有123家港股上市公司累计回购7.96亿股，合计回购金额为243.75亿港元。整体来看，回购股票数量和回购总金额有 所下降，但参与回购的上市公司家数超110家，这意味着在经历2025年港股市场上涨后，港股上市公司回购的热情依然没有减少。 从回购金额来看，腾讯控股、小米集团-W、舜宇光学科技、吉利汽车、泡泡玛特、巨子生物、先声药业、快手-W、百胜中国、百融云-W 位居前十，回购金额分别为63.58亿港元、23.90亿港元、8.69亿港元、5.60亿港元、3.48亿港元、1.40亿港元、1.26亿港元、1.00亿港元、 0.85亿港元、0.83亿港元。 从行业分布情况来看，既有腾讯控股、快手-W这样的互联网科技公司，也有泡泡玛特这样的非必需性消费公司，还有巨子生物、先声药 业这样的医药生物公司。 值得一提的是，2026年以来，腾讯控股在10个交易 ...

Profit Growth Overview - In 2025, the cumulative year-on-year profit growth rate for industrial enterprises was 0.6%, with December showing a significant increase of 5.3% compared to November's -13.1%[1] - The profit recovery is characterized as a "V-shaped" rebound, driven by improved production activity, narrowing PPI declines, and a substantial recovery in profit margins[1][4] Contributing Factors - The increase in profits is attributed to a combination of rising production volumes, improved pricing environments, and enhanced profit margins, with December's profit margin rising from 5.29% to 5.31%[5] - The industrial added value in December rose to 5.2%, up from 4.8% in November, indicating improved industrial production activity[5] Sector Performance - The profit share of upstream and midstream industries increased to 29.6% and 53.7%, respectively, while the downstream sector saw a slight decrease to 16.7%[6] - Upstream sectors like coal mining and non-ferrous metals showed strong profit recovery, while downstream sectors like automotive and food experienced profit contractions[6][14] Revenue Trends - Cumulative revenue growth for industrial enterprises in 2025 was 1.1%, with December showing a decline of 3.2%, indicating ongoing challenges in end-demand recovery[10] - The inventory growth rate for industrial finished products was 3.9%, signaling a shift from replenishment to destocking as companies respond to weak demand[10] Future Outlook - The sustainability of profit recovery is contingent on the strengthening of domestic demand and the continued effectiveness of policy measures[15] - Risks include external uncertainties and the potential for domestic demand recovery to fall short of expectations[16]

过去一年，吉林省推动产业转型升级，奥迪一汽新能源、红旗天工等一批新车型投产上市，新能源汽车 产量增长25.6%；吉化乙烯项目投产，总产能达190万吨，吉林化纤（000420）碳纤维产销量均跃升至 全球第1位，白城梅花建成世界最大的赖氨酸生产基地，产能占全球30%；新能源产业投资突破1300亿 元，新增开发装机超过600万千瓦；国电投大安、上海电气（601727）洮南、中能建松原等一批"绿电氢 氨醇"标志性项目建成投产，总产能全国领先；长春、松原、白城入选国家能源领域首批氢能区域试 点；全国首列氢能文旅列车成功投运；组建吉翼具身智能机器人公司，设立仿生机器人制造业创新中 心，抢占人工智能新赛道迈出坚实步伐。 过去一年，吉林省因地制宜发展新质生产力，实施光电、制储氢等10个聚力攻坚专项，部署关键技术攻 关项目459个；完成新建、重组11家全国重点实验室；"吉林一号"组网卫星增至144颗，带动上下游千余 家企业形成产业集群；省内转化科技成果增长24%，高技术制造业增加值增长13%。 "十四五"时期，吉林省发展质效持续提升，地区生产总值跨越3个千亿元台阶，达到1.5万亿元、增长 19.8%；人均地区生产总值增长25% ...

证券研究报告 主动超额延续，固收增强突围 ——公募基金重点产品/策略回顾与展望 证券分析师 | 陈 瑶 | 投资咨询资格编号：S1060524120003 | | --- | --- | | 郭子睿 | 投资咨询资格编号：S1060520070003 | | 任书康 | 投资咨询资格编号：S1060525050001 | | 研究助理 | | 高 越 一般从业资格编号：S1060124070014 胡心怡 一般从业资格编号：S1060124030069 2026年1月27日 请务必阅读正文后免责条款 报告摘要 2 • ETF回顾与展望：被动权益基金规模持续扩张，但增速有所放缓。资金流向方面，2025年资金由宽基流向行业主题ETF，具体来看2025年科技主 题ETF资金净流入额居前，其次为金融地产和周期主题ETF，伴随热门主题行情，热门概念主题ETF轮番吸引资金流入。2026年开年以来卫星/商 业航天、有色、AI主题ETF大幅净流入。参考美国共同基金发展历程，ETF发展趋势仍将延续，被动产品仍有发展空间。政策方面，优化了产品 注册与基准设置机制，通过一系列调降费率的举措，助力ETF充分发挥低费率、高透明度的工具 ...

Group 1 - The report outlines the grid trading strategy as a method of profiting from price fluctuations without predicting market trends, making it suitable for volatile markets [4][12] - Characteristics of suitable grid trading targets include being exchange-traded, having stable long-term trends, low transaction costs, good liquidity, and high volatility, with equity ETFs being identified as appropriate candidates [4][12] - The report highlights two key ETFs for grid trading: the Financial Technology ETF (159851.SZ) and the Medical ETF (512170.SH), emphasizing their potential benefits from market trends and innovations [4][13][16] Group 2 - The Financial Technology ETF is positioned to benefit from capital market reforms and the digital transformation of finance, with advancements in AI and blockchain driving efficiency and innovation in the sector [4][13] - The Medical ETF is catalyzed by the recent Nipah virus outbreak in India, which serves as a short-term driver, while the long-term growth is supported by the acceleration of innovative drug exports from China, showcasing the country's significant presence in the global pharmaceutical market [5][16] - The report suggests that investors can enhance returns by diversifying their grid trading strategies across different ETFs, combining various types and investment scopes to optimize risk management and capital utilization [16][19]

作为全国老字号嘉年华重点活动、广东"广货行天下"春季行动的重要组成部分，大湾区年味消费季活动 将持续至1月28日。位于陈家祠广场和1906科技园的老字号主题市集，汇集了广州及大湾区其他城市特 色老字号产品。王老吉国际罐、珠江啤酒茶啤新品、双鱼十五运会纪念球等一众广州老字号潮品齐齐亮 相，非遗体验、国潮演出、消费福利轮番上阵，让市民游客沉浸式感受广府老字号的传统底蕴与新潮活 力。 老字号是刻在广州这座千年商都基因里的瑰宝，广州拥有35个中华老字号、82个广东老字号、150个广 州老字号，涵盖食品、餐饮、医药、住宿、文化娱乐、工业制造等行业，构成了岭南商业文化的鲜活版 图。 近年来，广州以政策为支撑、以创新为引擎，为老字号高质量发展保驾护航。2025年出台的《广州老字 号认定管理办法》，将老字号认定移交政府部门规范管理，强化其在商贸流通、消费促进、质量管理等 方面的示范引领作用；将老字号纳入消费新业态新模式新场景试点城市重点支持范畴，对符合条件的项 目给予专项扶持。同时，发挥老字号振兴基金效能，2025年新增投资超1.8亿元，支持惠如楼、白云山 生物、万力轮胎等多个项目发展，建立国资收益后补助激励机制，指导企业" ...

智通财经1月27日讯（编辑 胡家荣）今日港股三大指数集体回暖。截至收盘，恒生指数涨1.35%，报27126.95点；科技指数涨0.50%，报5754.72点；国企指数 涨1.07%，报9244.88点。 | 27220.53 | | --- | | 27193.77 | | 27167.00 | | 27140.24 | | 27126.95 | | 27113.47 | | 27086.71 | | 27059.94 | | 27033.18 | | 27006.41 | | 26979.64 | | 26952.88 | | 26926.11 | | 26899.35 | | 26872.58 | | 26845.82 | | 26819.05 1-1 11-WL 11 -- - | 注：恒生指数的表现 今日市场 从市场表现来看，保险、半导体、AI应用等个股表现活跃，资金关注度显著提升；煤炭、互联网医疗、医药股则承压回调。 保险股多数上涨 估值修复动能增强 截至收盘，中国人寿(02628.HK)涨5.97%、友邦保险(01299.HK)涨4.09%、新华保险(01336.HK)涨3.56%。 | 代码 | ...

人民财讯1月27日电，商务部新闻发言人就中英经贸合作情况答记者问，有记者问：英国首相斯塔默将 于1月28日至31日对中国进行正式访问，这将是英国首相时隔8年首次访华。请问双方届时在经贸领域将 有哪些活动安排，有望取得哪些成果？如何评价中英经贸关系发展现状及未来合作前景？ 当前全球贸易保护主义加剧，中英均坚持自由贸易和维护多边贸易体制，双方将致力于优势互补、互利 共赢的经贸合作，推动货物和服务贸易协同发展，投资合作双向奔赴，不断拓展绿色能源、医疗健康、 创意产业、智能制造等领域合作空间。商务部愿与英方经贸主管部门一道，共同落实好两国领导人达成 的重要共识，加强经贸政策沟通，为双方企业合作创造公平、透明、法治化的营商环境，推动中英经贸 关系不断迈上新台阶。 答：中英互为重要经贸伙伴。长期以来，在两国领导人的战略引领下，中英经贸关系保持健康稳定发 展。2025年，中英双边货物贸易额达到1037亿美元，服务贸易额有望突破300亿美元，双向投资存量近 680亿美元。英国分别担任第二十五届投洽会、第四届消博会主宾国，中英两国务实合作充满活力。 据了解，届时斯塔默首相将率50余家英国大企业高管和机构代表随访，涵盖金融、医药 ...

Core Viewpoint - The recent Nipah virus outbreak in India has led to increased attention and investment in the A-share pharmaceutical sector, with significant capital inflows into medical ETFs despite some declines in stock prices [1][3]. Group 1: Market Activity - The medical ETF (159929) experienced a drop of over 1% today, following a previous day of gains, but attracted 64 million yuan in capital [1]. - Over the past 10 days, the ETF has seen net inflows for 9 days, accumulating nearly 300 million yuan [1]. - Trading activity remains robust, with intraday trading volume exceeding 120 million yuan [1]. Group 2: Nipah Virus Research - The Nipah virus outbreak in West Bengal, India, has resulted in deaths and the isolation of close contacts [3]. - A significant research study published in the journal Emerging Microbes & Infections confirms that the oral nucleoside drug VV116 shows promising antiviral activity against the Nipah virus, providing new hope for treatment and prevention [3]. Group 3: Company Updates - Sanofi's (三生国健) 2025 annual performance forecast indicates a net profit of approximately 2.9 billion yuan, reflecting a year-on-year increase of 311.35%, driven by a collaboration with Pfizer [4]. - Junshi Biosciences (君实生物) has completed the issuance of its first phase of technology innovation bonds for 2026, totaling 1 billion yuan, aimed at supporting drug research and development [4]. Group 4: Sector Trends - The pharmaceutical industry is expected to benefit from a favorable investment environment and policy support, particularly for innovative drugs and technologies [6][8]. - The medical manufacturing sector has shown a slight increase in industrial value added, while revenue and profit have seen minor declines [7]. - The healthcare expenditure in China has shown a year-on-year growth of 4.7% for the first 11 months of 2025, marking a recovery after two years of decline [7]. Group 5: Investment Strategies - Investment strategies for 2026 focus on innovation, international expansion, and marginal improvements in the pharmaceutical sector [8][9]. - Key areas of interest include innovative drugs, medical devices, and the integration of new technologies such as AI and brain-machine interfaces [8][9].